Daunorubicin liposomal (DaunoXome)

General information

Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. Liposomal preparation may increase accumulation in tumors. Daunorubicin binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.

Diseases for which it was used

• Acute myeloid leukemia
• Kaposi sarcoma

Patient drug information

• Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)
• Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)

History of changes in FDA indication

• 1996-04-08: Initial FDA approval as a first-line cytotoxic therapy for the treatment of advanced, HIV-associated Kaposi's sarcoma (KS). (Based on Gill et al. 1996)

Also known as

• Generic name: daunorubicin citrate liposome injection
• Brand name: DaunoXome